COMPANY RESEARCHBiohaven Ltd.
Biohaven is a clinical-stage biopharmaceutical company developing medicines for a range of neurological, immunological and oncological conditions. Its research includes extracellular protein degradation, other targeted therapeutics and selected antibody-drug conjugate programs. The company maintains research and development activities intended to translate disease mechanisms into drug candidates for rare and more common disorders. Biohaven is listed on the New York Stock Exchange under BHVN and has its corporate presence in New Haven, Connecticut. This concise entry identifies the company and its broad platform and therapeutic areas.
Company at a glance
Corporate information
- Company entity
- Biohaven Ltd.（current entity following the 2022 separation）
- Headquarters / principal office
- New Haven, CTSelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters.
Sources (1)
- Company-managed LinkedIn profile — self-reported locationChecked 2026-11-04; source publication date retained where stated
- Founded
- 2022
Sources (2)
- Biohaven company profileNot stated
- Biohaven Q2 2026 Organization Note2026-08
- Ownership / capital status
- Publicly tradedPublicly traded (NYSE: BHVN)
Sources (1)
- Official corporate reference
- https://www.biohaven.com/
Sources (1)
- Biohaven official websiteNot stated
- LinkedIn company page
- LinkedIn ↗
Sources (1)
- Biohaven company profileNot stated
- Latest financing / award identified
- 2026 (announced as completed by March) · Targeted block sale under ATM equity program · $125 million gross proceeds
Sources (1)
Gross proceeds from the targeted Janus Henderson block transaction only; not combined with net proceeds from other 2026 ATM sales or gross proceeds from the 2025 public offering.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Biohaven is a clinical-stage biopharmaceutical company developing medicines for a range of neurological, immunological and oncological conditions. Its research includes extracellular protein degradation, other targeted therapeutics and selected antibody-drug conjugate programs. The company maintains research and development activities intended to translate disease mechanisms into drug candidates for rare and more common disorders. Biohaven is listed on the New York Stock Exchange under BHVN and has its corporate presence in New Haven, Connecticut. This concise entry identifies the company and its broad platform and therapeutic areas.
NYSE: BHVN
extracellular protein degradation · targeted small molecules · ADC
neurology · immunology · oncology · rare diseases
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
A 2026-10-29 announcement reports Phase 3 BHV-1300 recruiting in Graves' disease and licensing of part of the Asian MoDE pan-IgG portfolio to Ono. Phase 3 BHV-1400 was still planned at that time.
Business, technology & evidence
- Biohaven is a clinical-stage biopharmaceutical company developing medicines for a range of neurological, immunological and oncological conditions. Its research includes extracellular protein degradation, other targeted therapeutics and selected antibody-drug conjugate programs. The company maintains research and development activities intended to translate disease mechanisms into drug candidates for rare and more common disorders. Biohaven is listed on the New York Stock Exchange under BHVN and has its corporate presence in New Haven, Connecticut. This concise entry identifies the company and its broad platform and therapeutic areas.
- SecuritiesNYSE: BHVN
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| BHV-1300 | IgG (including TSHR autoantibodies) / Gd-IgA1 · Graves' disease (BHV-1300) | Phase 3 | Human results reported by the source; see facts and original materials for type and quality |
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Planned Phase 3 BHV-1400 is not an initiated trial. IgG reduction and patient benefit require separate review.
- Biohaven Q3 2026 update ↗Biohaven · 2026-10-29
- Official issuer and R&D disclosure · Biohaven Ltd. ↗Biohaven Ltd. ·
- Biohaven official website ↗Biohaven · Not stated
- Biohaven company profile ↗Biohaven / LinkedIn · Not stated
- Biohaven Q2 2026 Organization Note ↗Biohaven / SEC · 2026-08
- Biohaven FY2025 Results and 2026 Financing Update ↗Biohaven · 2026-03-02
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.